UK Healthtech Startup Nul Secures $1M Seed Round Led by Dmg Ventures and BYVP
•February 16, 2026
0
Participants
Why It Matters
Nul’s evidence‑based, subscription‑based model tackles a massive, underserved segment of healthcare, promising scalable, discreet treatment for harmful drinking. Its success could spur broader digital innovation in addiction care and attract further capital to the space.
Key Takeaways
- •Nul raised $1M seed led by dmg ventures
- •Platform combines telehealth, naltrexone, and behavioral support
- •Over £300k ARR achieved with 120+ customers
- •Focuses on reduction, not mandatory abstinence
- •Plans UK launch, US expansion, and crowdfunding
Pulse Analysis
Alcohol use disorder remains a global health crisis, yet treatment innovation has lagged behind other chronic conditions. Recent telehealth breakthroughs have reshaped weight‑loss and mental‑health services, demonstrating that digital delivery can lower barriers and improve adherence. Nul’s entry into this space aligns with a broader industry shift toward remote, medication‑assisted therapies, positioning it to capture demand from consumers seeking discreet, flexible solutions.
Nul’s platform leverages the Sinclair Method, pairing prescription naltrexone with structured digital guidance to reduce cravings without demanding total abstinence. By offering virtual clinician visits, ongoing support, and a subscription model, the startup creates a continuous care loop that mirrors successful SaaS health products. Early traction—over £300,000 annualised revenue from 120+ users—signals strong organic demand and validates the market appetite for evidence‑based, reduction‑focused treatment pathways.
The $1 million seed round not only finances a nationwide UK rollout but also fuels product development, regulatory navigation, and a planned US expansion. As investors increasingly target health‑tech solutions that combine pharma and software, Nul’s model could attract further capital and inspire competitors to modernise addiction care. Successful scaling may also influence policy, encouraging insurers and public health systems to reimburse digital alcohol‑reduction programs, thereby expanding access and reducing societal costs associated with harmful drinking.
Deal Summary
Nul, a UK‑based healthtech startup focused on alcohol reduction, announced a $1 million seed funding round. The round was led by dmg ventures and BYVP, with participation from a group of angel investors, and will fund the company’s UK commercial launch and international expansion plans.
Article
Source: Tech.eu
Nul, a UK-based healthtech startup developing a supported alcohol reduction platform that combines clinical care and prescription medication, has raised $1 million in seed funding. The round was led by dmg ventures and BYVP, with participation from a group of angel investors.
Alcohol use disorder and harmful drinking affect millions of people globally, while treatment options have seen limited innovation in recent decades. Nul aims to address this gap with medication- and therapy-supported reduction models designed for individuals who want to reduce their alcohol consumption without requiring immediate or complete abstinence.
Founded by Matus Maar, Nul is building a telehealth platform that integrates clinical care, prescription medication, digital treatment pathways, and behavioural support. The company’s programme is based on naltrexone, a medication used to reduce alcohol cravings by targeting reward pathways.
Delivered through a fully remote subscription service, the programme includes virtual consultations, ongoing clinical support, and structured digital guidance based on The Sinclair Method.
Commenting on the company’s mission, Matus Maar, founder and CEO of Nul, said that alcohol reduction remains one of the largest areas in healthcare that has seen relatively limited modernisation.
Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.
Nul launched a UK test phase in summer 2025 and has onboarded more than 120 paying customers, reaching an annualised revenue run rate of over £300,000 within its first months, driven largely by organic demand and word-of-mouth.
The seed funding will support the company’s full UK commercial launch, expansion of its clinical and product teams, scaling of customer acquisition, and preparation for future international expansion, including the US market.
Alongside the seed round, Nul plans to launch a crowdfunding campaign on Republic Europe, allowing retail investors to participate in the round and support the company’s next phase of growth.
0
Comments
Want to join the conversation?
Loading comments...